Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: A one year follow-up

A. Quatraro, G. Consoli, A. Ceriello, D. Giugliano

Research output: Contribution to journalArticle

Abstract

We studied the influence of chronic sulfonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs. Thirty diabetics were allocated at random into two groups, each consisting of 15 subjects: group A continued insulin treatment, while group B received combined insulin plus sulfonylurea. Daily doses of the sulfonylurea gliclazide ranged from 40 to 240 mg, and dose adjustment was made on the basis of periodic monthly control. This treatment (12 months) caused a significant improvement of both diurnal glucose profile and HbA1 levels; the beta-cell secretory response to 1 mg glucagon was significantly increased at the end of the study. There was on average a 40% reduction of the daily insulin dose in the diabetics receiving combined treatment. None of these improvements were seen in the control group receiving only insulin for the same period of time. We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin.

Original languageEnglish
Pages (from-to)315-318
Number of pages4
JournalDiabete et Metabolisme
Volume12
Issue number6
Publication statusPublished - 1986

Fingerprint

Insulin
Pharmaceutical Preparations
Therapeutics
Gliclazide
Glucose
Glycosylated Hemoglobin A
Glucagon
Control Groups

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs : A one year follow-up. / Quatraro, A.; Consoli, G.; Ceriello, A.; Giugliano, D.

In: Diabete et Metabolisme, Vol. 12, No. 6, 1986, p. 315-318.

Research output: Contribution to journalArticle

@article{be207c0e6df94d7dbf10a03144e35ce3,
title = "Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: A one year follow-up",
abstract = "We studied the influence of chronic sulfonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs. Thirty diabetics were allocated at random into two groups, each consisting of 15 subjects: group A continued insulin treatment, while group B received combined insulin plus sulfonylurea. Daily doses of the sulfonylurea gliclazide ranged from 40 to 240 mg, and dose adjustment was made on the basis of periodic monthly control. This treatment (12 months) caused a significant improvement of both diurnal glucose profile and HbA1 levels; the beta-cell secretory response to 1 mg glucagon was significantly increased at the end of the study. There was on average a 40{\%} reduction of the daily insulin dose in the diabetics receiving combined treatment. None of these improvements were seen in the control group receiving only insulin for the same period of time. We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin.",
author = "A. Quatraro and G. Consoli and A. Ceriello and D. Giugliano",
year = "1986",
language = "English",
volume = "12",
pages = "315--318",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs

T2 - A one year follow-up

AU - Quatraro, A.

AU - Consoli, G.

AU - Ceriello, A.

AU - Giugliano, D.

PY - 1986

Y1 - 1986

N2 - We studied the influence of chronic sulfonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs. Thirty diabetics were allocated at random into two groups, each consisting of 15 subjects: group A continued insulin treatment, while group B received combined insulin plus sulfonylurea. Daily doses of the sulfonylurea gliclazide ranged from 40 to 240 mg, and dose adjustment was made on the basis of periodic monthly control. This treatment (12 months) caused a significant improvement of both diurnal glucose profile and HbA1 levels; the beta-cell secretory response to 1 mg glucagon was significantly increased at the end of the study. There was on average a 40% reduction of the daily insulin dose in the diabetics receiving combined treatment. None of these improvements were seen in the control group receiving only insulin for the same period of time. We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin.

AB - We studied the influence of chronic sulfonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs. Thirty diabetics were allocated at random into two groups, each consisting of 15 subjects: group A continued insulin treatment, while group B received combined insulin plus sulfonylurea. Daily doses of the sulfonylurea gliclazide ranged from 40 to 240 mg, and dose adjustment was made on the basis of periodic monthly control. This treatment (12 months) caused a significant improvement of both diurnal glucose profile and HbA1 levels; the beta-cell secretory response to 1 mg glucagon was significantly increased at the end of the study. There was on average a 40% reduction of the daily insulin dose in the diabetics receiving combined treatment. None of these improvements were seen in the control group receiving only insulin for the same period of time. We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin.

UR - http://www.scopus.com/inward/record.url?scp=0022893785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022893785&partnerID=8YFLogxK

M3 - Article

C2 - 3545931

AN - SCOPUS:0022893785

VL - 12

SP - 315

EP - 318

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 6

ER -